O
OctoPlus
Develops pharmaceutical formulation solutions
About OctoPlus
In 1995, from the biotech hub of Leiden in the Netherlands, two founders, Joost Holthuis and Daan Crommelin, started a company with a specific focus. That company was OctoPlus, a specialty pharmaceutical firm centered on the complex world of drug delivery. Their business was not about discovering new blockbuster drugs, but rather a more nuanced play: developing and manufacturing advanced, injectable formulations of new and existing medicines for other pharmaceutical companies. They built expertise in creating controlled-release and difficult-to-formulate products, helping partners move from the lab to the clinic. This strategy led them to a public listing on the Euronext Amsterdam exchange, a significant step for the Dutch company. The pivotal chapter in the OctoPlus story came in late 2012. Indian pharmaceutical giant Dr. Reddy's Laboratories announced it would acquire OctoPlus for around €27.4 million. For Dr. Reddy's, this wasn't just a purchase; it was a strategic move to acquire specialized technological capabilities and establish a research base in the heart of the European biotech scene. By 2013, the deal was complete, and OctoPlus was integrated, becoming a key research center for complex injectables for its new parent company.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Oct 2012 | $36M | — | Dr. Reddy’s Laboratories | — |
| EARLY VCEquity / VC | Feb 2011 | $0 | — | Generis Capital Partners | — |
Growth signals
Latest recorded traffic for OctoPlus is 0 monthly website visits. OctoPlus's team grew 7700% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
OctoPlus in the Leiden ecosystem
The OctoPlus office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
SR One
EQT Life Sciences
Innoven Partners
Generis Capital Partners
Other known investors2 additional known investors
Dr. Reddy’s Laboratories
Signet Healthcare Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OctoPlus on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OctoPlus’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









